Hospital to leverage Glytec’s eGMS® solution for advanced glycemic management decision support

March 16, 2016 09:00 AM Eastern Daylight Time

WALTHAM, Mass.--(BUSINESS WIRE)-Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, announced today that Riverside Medical Center (RMC), has selected the company’s eGlycemic Management System® (eGMS®) to further strengthen its Diabetes Management Program. eGMS® enables providers, payers and patients to control glucose levels and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.

In part 1 of this Exclusive Interview, DIC Publisher Steve Freed talks with Dr. Andy Rhinehart to learn about a new insulin dosing support software that is used in conjunction with doctor intervention.

Andy Rhinehart, MD, FACP, FACE, CDE, BC-ADM, CDTC, is the Chief Medical Officer at Glytec Systems, a clinical information technology company dedicated to the mission of improving insulin management and glycemic control. Dr. Rhinehart previously served as a diabetologist and the program director of the Johnston Memorial Diabetes Care Center and Johnston Memorial Center for Comprehensive Wound Care in Abingdon, Va. He was also the chairman of the ADA’s Primary Care Advisory Group and the first physician to be Board Certified in Advanced Diabetes Management (BC-ADM) by the American Association of Diabetes Educators.

Second Allowance Covers Its Unique Insulin Administration Method

November 18, 2015 09:00 AM Eastern Standard Time

WALTHAM, Mass.--(BUSINESS WIRE)--Glytec, the pioneer and leader in providing innovative glucose management software solutions, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application directed toward a method of administering insulin proven to improve patient outcomes compared to antiquated paper protocols. The method entails selecting a precise subcutaneous insulin treatment for each patient based on blood glucose measurements and other patient information, and administering the selected treatment.

Study leveraging Glytec’s Glucommander™ IV Demonstrated a Lower Rate of Admissions and Future Hospitalizations, Resulting in a Cost Savings of $78,000 within 12 months.

Waltham, MA — February 9, 2016 – Glytec, the pioneer and leader in providing innovative glucose decision support software solutions for effective diabetes management, is pleased to share the results of a study conducted in collaboration with Wake Forest Medical School, Eastern Virginia Medical School, and Sentara Healthcare. The study demonstrated intensive insulin therapy used in emergency departments (ED) is useful in treating patients with mild to moderate diabetic ketoacidosis (DKA), resulting in a lower rate of admissions and future admissions to the hospital along with significant cost savings.

Ninety percent of study participants achieved target glucose within 3 weeks and achieved an average reduction in estimated A1C of 3.0%.

Waltham, MA — November 3, 2015 – Glytec,the pioneer and leader in providing innovative glucose management software solutions, announced today that Glucommander™, a component of the company’s eGMS® platform, achieved its 30-day primary efficacy endpoint in a study evaluating the average A1C reduction in an outpatient setting for persons with type 1 and type 2 diabetes.

According to study results, Glucommander was effective at titrating insulin doses and quickly achieving glucose control, with low rates of hypoglycemia, for 22 patients, regardless of the severity of their diabetes. The average starting A1C was 10.4% and the average estimated A1C (eA1C) at 30-days was 7.4%. A larger study looking at 3-month reduction in A1C will be published in the near future.

Page 1 of 6